Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination

Vaccine

Volumn 18, Issue 14, 2000, Pages 1393-1401

  Bautista López, Norma ^a   Ward, Brian J ^a   Mills, Elaine ^b   McCormick, Deirdre ^b   Martel, Nathalie ^a   Ratnam, Sam ^c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c Newfoundland and Labrador Public Health Laboratory   (Canada)

Author keywords

Cell mediated immunity; Measles vaccine; Vaccine failure

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CANADA; CHILD; FEMALE; HUMAN; INFECTION SENSITIVITY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEASLES; PRIORITY JOURNAL; TREATMENT FAILURE; VACCINATION;

ADOLESCENT; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFANT; LYMPHOCYTE ACTIVATION; MALE; MEASLES VACCINE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VACCINE; PROSPECTIVE STUDIES; RUBELLA VACCINE; VACCINATION; VACCINES, COMBINED;

EID: 0343775798     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00396-5     Document Type: Article

References (38)

1. Markowitz L.E., Katz S.L. Measles vaccine. Plotkin S.A., Mortimer E.A. Vaccines. 2nd ed. 1994;229-276 Saunders, Philadelphia.
2. Measles: United States, 1990. MMWR. 40:1991;369-372.
3. Boulianne N., DeSerres G., Duval B., et al. Épidémie majeure de rougeole dans la région de Québec malgré une couverture vaccinale de 99%. Can. Pub. Health J. 82:1991;189-190.
4. The measles epidemic: the problems, the barriers and recommendations. JAMA. 18:1991;671-676.
5. Consensus Conference on Measles. Can. Dis. Wkly Rep. 19:1993;72-79.
6. Tulchinsky T.H., Ginsberg G.M., Abed Y., Angeles M.T., Akukwe C., Bonn J. Measles control in developing and developed countries: the case for a two-dose policy. Bull. WHO. 71:1993;93-103.
7. Hayden G.F. Measles vaccine failure: a survey of causes and means of prevention. Clin. Pediatr. 18:1979;155-167.
8. Good R.A., Zak S.J. Disturbances in gamma globulin synthesis as "experiments of nature" Pediatrics. 18:1956;109-149.
9. Ruckdeschel J.C., Graziano K.D., Mardiney M.R. Jr. Additional evidence that the cell-associated immune system is the primary host defense against measles (rubeola). Cell Immunol. 17:1975;11-18.
10. Samb B., Aaby P., Whittle H.C., Seck A.M.C., Rahman S., Bennett J., Markowitzs L., Simondon F. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 14:1995;203-209.
11. Mitus A., Holloway, Evens E.A., Enders J.F. Attenuated measles vaccine in children with acute leukemia. Am. J. Dis. Child. 103:1965;413-418.
12. Markowitz L.E., Chandler F.W., Roldan E.O., et al. Fatal measles pneumonia without a rash in a child with AIDS. J. Infect. Dis. 158:1988;480-483.
13. McFarland H.F., Pedone C.A., Mingioli E.S., McFarlin D.E. The response of human lymphocyte subpopulations to measles, mumps and vaccinia viral antigens. J. Immunol. 125:1980;221-22562.
14. Greenstein JI, McFarland HF. Response of human lymphocytes to measles virus after natural infection. Infect Immun 1983;40:198-204.
15. Rose J.W., Bellini W.J., McFarlin D.E., McFarland H.F. Human cellular response to measles virus polypeptides. J. Virol. 49:1984;988-991.
16. Whittle H., Dossetor J., Oduloji A., Bryceson A.D.M., Greenwood B.M. Cell mediated immunity during natural measles virus infection. J. Clin. Invest. 62:1978;678-685.
17. Krause P.J., Cherry J.D., Carney J., Naiditch M.J., O'Connor K. Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories. Am. J. Dis. Child. 134:1980;567-571.
18. + cytotoxic T cell clones. J. Immunol. 142:1989;2847-2854.
19. Jacobson S., Sekaly R.P., Jacobson C.L., McFarland H.F., Long E.O. HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J. Virol. 63:1989;1756-1762.
20. + T cells. J. Exp. Med. 184:1996;864-871.
21. Gallimore A., Dumrese, Hengartner H., Zinkernagel R.M., Rammensee H.G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1998;1647-1657.
22. Ward B.J., Boulianne N., Ratnam S., Guiot M.C., Couillard M., DeSerres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferation despite limited serum antibody production after revaccination. J. Infect. Dis. 172:1995;1591-1595.
23. Pabst H.F., Spady D.W., Carson M.M., Stelfox H.T., Beeler J.A., Krezolek M.P. Kinetics of immunologic response to MMR vaccination. Vaccine. 15:1997;10-14.
24. Gans H.A., Arvin A.M., Galinus J., Logan L., DeHovitz R., Maldonado Y. Deficiency of the humoral response to measles vaccine in infants immunized at age six months. JAMA. 280:1998;527-532.
25. van Binnendijk R.S., Poelen M.C., van Amerongen G., de Vries P., Osterhaus A.D. Protective immunity in macaques vaccinated with live attenuated, recombinant and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:1997;524-532.
26. Pauksen K., Linde A., Lonnerholm G., Ljungman P., Sjolin J. Influence of the specific T cell response on seroconversion after measles vaccination in autologous bone marrow transplant patients. Bone Marrow Transplant. 18:1996;969-973.
27. Ratnam S., Gadag V., West R., Burris J., Oates E., Stead F., Boulianne N. Comparison of commercial enzyme linked immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J. Clin. Microbiol. 33:1995;811-815.
28. Ward B.J., Aouchiche S., Martel N., Bertley F.M.N., Bautista-López N., Serhir B., Ratnam S. Measurement of measles virus-specific neutralization antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. Diag. Micribiol. Infect. Dis. 33:1999;147-152.
29. Ballew H.C. Neutralization. Specter S., Lancz G.J. Clinical virology manual. 1986;194-195 Elsevier Science, New York.
30. Chen R.T., Goldbaum G.M., Wassilak S.G.F., Markowitz L.E., Orenstein W.A. An explosive point-source measles outbreak in a highly vaccinated population. Am. J. Epidemiol. 129:1989;173-182.
31. Black F.L., Berman L.L., Libel M., Reichelt C.A., Pinheiro F.D., Travassos da Rosa A., Figueira F., Siqueira Gonzales E. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccinationInadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull. WHO. 62:1984;315-319.
32. Matson D.O., Byington C., Canfield M., Albreacht P., Feigin R.D. Investigation of a measles outbreak in a fully vaccinated school population, including serum studies before and after revaccination. Pediatr. Infect. Dis. J. 12:1993;292-299.
33. Cohn M.L., Robinson E.D., Faerber M., Thomas D., Geyer S., Peters S., Martin M., Martin A., Sobel D., Jones R., Larkin L., Richert J.R. Measles vaccine failure: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and adults. Pediatr. Infect. Dis. J. 13:1994;34-38.
34. Hermaszewski R.A., Webster A.D. Primary hypogammaglobulinemia: a survey of the clinical manifestations and complications. Q. J. Med. 86:1993;31-36.
35. Locksley R.M., Wolson C.B. Cell-mediated immunity and its role in host defense. Mandel G.L., Bennett J.E., Dolin R. Principles and practice of infectious diseases. 4th ed. 1995;102-149 Churchill Livingstone, New York.
36. Guris D., McCready J., Watson J.C., Atkinson W.L., Heath J.L., Bellini W., Polloi A. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr. Infect. Dis. J. 15:1996;1082-1086.
37. Sutcliffe P.A., Rea E. Outbreak of measles in a highly vaccinated secondary school population. CMAJ. 155:1996;1407-1413.
38. De Serres G., Boulianne N., Meyer F., Ward B.J. Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol. Infect. 115:1995;315-323.